MPLA (Monophosphoryl Lipid A)

MPLA (Monophosphoryl Lipid A)
Product Description

MPLA (Monophosphoryl Lipid A) refers to monophosphoryl lipid A, an effective, safe and non-toxic vaccine adjuvant. It is a highly specific TLR4 agonist that can activate the natural immune response, induce the production of cytokines, and increase the antigen uptake, antigen presentation and activation of specific T cells by antigen-presenting cells such as dendritic cells and monocytes. However, as a bacterial derivative, natural MPLA has many risks such as microbial contamination, unstable quality and sustainable supply. Therefore, our company has developed a fully synthetic monophosphoryl lipid A with a clear product structure and controllable quality, which can ensure the safety and effectiveness of vaccines.

Read more Show less

NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.

  • CN
  • 2023
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Primary activities
Biopharmaceutical
Cosmetic Ingredients
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    （1）Adopting full synthesis process, stable structure and high product purity (more than 97%);
    （2）Self-developed process route and product structure, fully confirmed by mass spectrometry, nuclear magnetic resonance, etc.;
    （3）The immunogenicity and safety of various vaccine applications are equivalent to those of bacterial extraction sources;
    （4）Water content, microbial limits, residual solvents and other items all meet the requirements for vaccine use;
    （5）Sufficient safety research and stability inspection of intermediate products and finished products have been carried out;
    （6）Perfect GMP production conditions, large product batches and stable supply.

  • Supplied from
    China
More specifications Fewer specifications
Sales Markets
Show more Show less

NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.

  • CN
  • 2023
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Primary activities
Biopharmaceutical
Cosmetic Ingredients
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from NANJING WELL PHARMACEUTICAL GROUP CO.,LTD. (4)

  • Poloxamer 188 / Poloxamer 407

    Product Poloxamer 188 / Poloxamer 407

    Emulsifier, solubilizer, wetting agent and suspension stabilizer for liquid oral and topical preparations.

    Can be used as a coating plasticizer for oral solid preparations.

    As gel base for liquid or semi-solid formulations.

  • Polyethylene Glycol 3350 API / Polyethylene Glycol 4000 API

    Product Polyethylene Glycol 3350 API / Polyethylene Glycol 4000 API

    By precise polymerization technology and advanced refining post-processing technology to ensure batch-to-batch repeatability.
    Spray granulation process gives good flowability, and the particle size can be customized according to the requirements of clients.
    The product quality meets the domestic and ...
  • Polysorbate 80（For Injection）

    Product Polysorbate 80（For Injection）

    Nonionic surfactant, solubilizer, wetting agent, plasticizer. It also can be used as oil-in-water emulsifier.

  • QS-21

    Product QS-21

    QS-21 is an isomeric saponin extracted from the bark of the soap tree (Quillaja Saponaria). It consists of one or more hydrophilic glycoside groups connected to lipophilic triterpenoid derivatives, and contains about 65% QS-21-apiose and 35% QS-21-xylose. Its function is to stimulate antibody-based and cel...